NASDAQ:SNNA - Sienna Biopharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$15.89 -0.56 (-3.40 %)
(As of 06/20/2018 04:00 PM ET)
Previous Close$16.45
Today's Range$14.78 - $16.55
52-Week Range$13.37 - $29.25
Volume74,700 shs
Average Volume90,311 shs
Market Capitalization$335.86 million
P/E Ratio-3.06
Dividend YieldN/A
BetaN/A
Sienna Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of topical products in medical dermatology and aesthetics. The company's lead product candidates include SNA-120, a first-in-class inhibitor of tropomyosin receptor kinase A, which is in a Phase IIb clinical trial for the treatment of pruritus or itch associated with psoriasis, as well as for psoriasis; and SNA-125, a topical janus kinase 3 inhibitor that is in Phase I/II clinical trials for the treatment of atopic dermatitis, psoriasis, and pruritus. It also develops SNA-001, a topical suspension of silver particles, which is in pivotal clinical trials for the treatment of acne, as well as for the reduction of light-pigmented hair, including white, gray, blonde, light brown, and light red hair. The company was formerly known as Sienna Labs, Inc. and changed its name to Sienna Biopharmaceuticals, Inc. in February 2016. Sienna Biopharmaceuticals, Inc. was founded in 2010 and is headquartered in Westlake Village, California.

Receive SNNA News and Ratings via Email

Sign-up to receive the latest news and ratings for SNNA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SNNA
CUSIPN/A
Phone818-629-2256

Debt

Debt-to-Equity RatioN/A
Current Ratio6.84
Quick Ratio6.84

Price-To-Earnings

Trailing P/E Ratio-3.06
Forward P/E Ratio-5.46
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$4.44 per share
Price / Book3.58

Profitability

EPS (Most Recent Fiscal Year)($5.19)
Net Income$-50,540,000.00
Net MarginsN/A
Return on Equity-110.53%
Return on Assets-45.87%

Miscellaneous

Employees47
Outstanding Shares20,730,000

Sienna Biopharmaceuticals (NASDAQ:SNNA) Frequently Asked Questions

What is Sienna Biopharmaceuticals' stock symbol?

Sienna Biopharmaceuticals trades on the NASDAQ under the ticker symbol "SNNA."

How were Sienna Biopharmaceuticals' earnings last quarter?

Sienna Biopharmaceuticals Inc (NASDAQ:SNNA) announced its quarterly earnings data on Monday, May, 14th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.70) by $0.15. View Sienna Biopharmaceuticals' Earnings History.

What price target have analysts set for SNNA?

4 brokers have issued 12-month target prices for Sienna Biopharmaceuticals' stock. Their forecasts range from $21.00 to $50.00. On average, they expect Sienna Biopharmaceuticals' share price to reach $32.25 in the next year. View Analyst Ratings for Sienna Biopharmaceuticals.

Who are some of Sienna Biopharmaceuticals' key competitors?

Who are Sienna Biopharmaceuticals' key executives?

Sienna Biopharmaceuticals' management team includes the folowing people:
  • Dr. Frederick C. Beddingfield III, CEO, Pres & Director (Age 53)
  • Dr. Todd Harris, Head of Corp. Devel. & Director (Age 39)
  • Mr. John W. Smither, Chief Financial Officer (Age 65)
  • Mr. Majed Kheir, VP of Operations (Age 40)
  • Dr. Silvio Traversa BSc Ph.D., Chief Scientific Officer (Age 48)

When did Sienna Biopharmaceuticals IPO?

(SNNA) raised $64 million in an initial public offering (IPO) on Thursday, July 27th 2017. The company issued 4,300,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Cowen and BMO Capital Markets acted as the underwriters for the IPO.

Has Sienna Biopharmaceuticals been receiving favorable news coverage?

Headlines about SNNA stock have been trending somewhat positive on Wednesday, according to Accern Sentiment. Accern rates the sentiment of news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Sienna Biopharmaceuticals earned a coverage optimism score of 0.09 on Accern's scale. They also gave media headlines about the company an impact score of 46.40 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.

Who are Sienna Biopharmaceuticals' major shareholders?

Sienna Biopharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (4.41%), Victory Capital Management Inc. (2.27%), IFP Advisors Inc (0.87%), Northern Trust Corp (0.61%), Cohen Capital Management Inc. (0.55%) and Tiverton Asset Management LLC (0.27%). Company insiders that own Sienna Biopharmaceuticals stock include Dennis M Fenton, Keith R Leonard, Paul F Lizzul, Richard D Peterson, Robert J More, Timothy K Andrews and Todd Harris. View Institutional Ownership Trends for Sienna Biopharmaceuticals.

Which major investors are selling Sienna Biopharmaceuticals stock?

SNNA stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc.. Company insiders that have sold Sienna Biopharmaceuticals company stock in the last year include Robert J More and Todd Harris. View Insider Buying and Selling for Sienna Biopharmaceuticals.

Which major investors are buying Sienna Biopharmaceuticals stock?

SNNA stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., IFP Advisors Inc, Cohen Capital Management Inc., Northern Trust Corp, Tiverton Asset Management LLC, Schwab Charles Investment Management Inc., Crestwood Advisors Group LLC and Meadow Creek Investment Management LLC. Company insiders that have bought Sienna Biopharmaceuticals stock in the last two years include Dennis M Fenton, Keith R Leonard, Paul F Lizzul, Richard D Peterson and Timothy K Andrews. View Insider Buying and Selling for Sienna Biopharmaceuticals.

How do I buy shares of Sienna Biopharmaceuticals?

Shares of SNNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Sienna Biopharmaceuticals' stock price today?

One share of SNNA stock can currently be purchased for approximately $15.89.

How big of a company is Sienna Biopharmaceuticals?

Sienna Biopharmaceuticals has a market capitalization of $335.86 million. The company earns $-50,540,000.00 in net income (profit) each year or ($5.19) on an earnings per share basis. Sienna Biopharmaceuticals employs 47 workers across the globe.

How can I contact Sienna Biopharmaceuticals?

Sienna Biopharmaceuticals' mailing address is 30699 Russell Ranch Road Suite 140, Westlake Village CA, 91362. The company can be reached via phone at 818-629-2256 or via email at [email protected]


MarketBeat Community Rating for Sienna Biopharmaceuticals (SNNA)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  79 (Vote Outperform)
Underperform Votes:  92 (Vote Underperform)
Total Votes:  171
MarketBeat's community ratings are surveys of what our community members think about Sienna Biopharmaceuticals and other stocks. Vote "Outperform" if you believe SNNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SNNA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.